BBV152

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name

BBV152

Accession Number

DB15847

Description

BBV152 is a vaccine candidate created by the Indian Council of Medical Research (ICMR). The candidate, a whole virion inactivated SARS-CoV-2 vaccine, was developed from a well-known SARS-CoV-2 strain and a vero cell platform (CCL-81) with adjuncts of either aluminum hydroxide gel (Algel) or a novel TLR7/8 agonist adsorbed gel. The components of the vaccine include BBV152A, BBV152B, and BBV152C. Animal studies in mice, rats, and rabbits reported BBV152 immunogenicity at two separate antigen concentrations with both types of adjuvants. The formulation with the TLR7/8 adjuvant specifically induced significant Th1 biased antibody responses and increased SARS-CoV-2 lymphocyte responses. Thus, as of July 2020, BBV152 is in Phase 1/2 clinical trials assessing safety and immunogenicity in humans (NCT04471519).

Type

Biotech

Groups

Investigational

Biologic Classification

Vaccines
Inactivated

Synonyms

BBV-152
Covaxin
Whole-Virion Inactivated SARS-CoV-2 Vaccine

External IDs

BBV152

Pharmacology

Indication: Not Available
Contraindications & Blackbox Warnings: Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Learn about our commercial Adverse Effects data.
Learn More
Toxicity: Not Available
Affected organisms: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Interactions

Drug Interactions: This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions: Not Available

Chemical Identifiers

UNII: Not Available
CAS number: Not Available

References

General References

Rego GNA, Nucci MP, Alves AH, Oliveira FA, Marti LC, Nucci LP, Mamani JB, Gamarra LF: Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2. Vaccines (Basel). 2020 Aug 25;8(3). pii: vaccines8030474. doi: 10.3390/vaccines8030474. [PubMed:32854391]
Vaccine News [Link]
Deadline News Article [Link]

External Links

Not Available

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
3	Recruiting	Prevention	Coronavirus (SARS-CoV) / Coronavirus Disease 2019 (COVID‑19)	1
1, 2	Active Not Recruiting	Prevention	Coronavirus Disease 2019 (COVID‑19)	1